The effect of rifampicin on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. 1996

Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine, Centre Hospitalier Universitaire, Nantes, France.

Using the dynamic chequerboard technique, we confirmed that rifampicin produces a synergistic bactericidal effect when combined with amikacin or netilmicin. Adaptive resistance was suppressed when rifampicin was added to aminoglycoside after, but not during, first exposure to amikacin or netilmicin. The effect of rifampicin on adaptive resistance could account for the synergy between rifampicin and aminoglycosides.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000222 Adaptation, Physiological The non-genetic biological changes of an organism in response to challenges in its ENVIRONMENT. Adaptation, Physiologic,Adaptations, Physiologic,Adaptations, Physiological,Adaptive Plasticity,Phenotypic Plasticity,Physiological Adaptation,Physiologic Adaptation,Physiologic Adaptations,Physiological Adaptations,Plasticity, Adaptive,Plasticity, Phenotypic
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
October 2003, Pathologie-biologie,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
April 2003, Antimicrobial agents and chemotherapy,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
October 1991, Nihon rinsho. Japanese journal of clinical medicine,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
January 1974, Pathologia et microbiologia,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
June 2021, Antibiotics (Basel, Switzerland),
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
March 2007, Antimicrobial agents and chemotherapy,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
July 1979, The Journal of antimicrobial chemotherapy,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
April 1990, The Journal of antimicrobial chemotherapy,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
May 1989, Journal of medical microbiology,
Y Q Xiong, and J Caillon, and H Drugeon, and G Potel, and D Baron
March 2011, International journal of antimicrobial agents,
Copied contents to your clipboard!